GSK
NEWS
The U.S. Centers for Disease Control and Prevention warned the public yesterday to be prepared for it to spread in the U.S., indicating it was “when,” not “if.”
The FDA is reviewing the sNDA under the Real-Time Oncology Review (RTOR) pilot program, which could speed up the process for potential approval.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The brands Stada is picking up include venous treatment Venoruton, Coldrex for colds, Cetebe vitamin C supplements, Mebucaine for sore threats and Tavegyl for allergies, among others.
Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.
Vectura Group plc announces a key appointment to support innovation, customer focus and growth as the company continues with its strategic development as a leading inhalation specialist in the pharmaceutical services space.
JOBS
IN THE PRESS